Last updated 10 days ago

A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C

1016 patients around the world
Available in Spain, Brazil, Mexico, United States
Dose Optimization, Part A, and Part B are randomized. Safety Lead-In for Part B is single arm, non-randomized.
Eli Lilly and Company
28Research sites
1016Patients around the world
This study is for people with
Lung cancer
Non-small cell lung carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Instituto Do Câncer Do Ceará ICC
Rua Papi Júnior, 1222 - Rodolfo Teófilo, Fortaleza - CE, 60430-230
Hospital Sírio- Libanês Brasilia
SGAS 613/614 Conjunto E Lote 95, SGAS II SGAS 613 - Asa Sul, Brasília - DF, 70200-730
Hospital Brasília
Shis Qi 15 - SHIS QI 15 - Lago Sul, Brasília - DF, Brazil
Hospital São Domingos
Av. Jerônimo de Albuquerque, nº 540, Bequimão São Luís - MA
Oncominas
Rua Benedito Valdetário e Silva, 80 - Fatima, Pouso Alegre - MG, 37550-000, Brazil
Hospital Do Cancer de Londrina
Londrina, 86015-520
Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica
Natal, Rio Grande Do Norte, 59075-740
ONCOSITE - Centro de Pesquisa Clinica em Oncologia
Ijui, 98700-000
Centro Universitário Faculdade de Medicina do ABC (FMABC)
Av. Lauro Gomes, 2000 - Vila Sacadura Cabral, Santo André - SP, 09060-870
Beneficência Portuguesa de São Paulo
R. Maestro Cardim, 637 - Bela Vista, São Paulo - SP, 01323-001
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy